Caffeine

Generic Name: Caffeine

Brand Names: Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₀N_₄O_₂

CAS Number: 58-08-2

Unique Ingredient Identifier: 3G6A5W338E

Background: Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, whic...

Indication: Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broa...

Associated Conditions: Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain

Associated Therapies: Analgesia, Antacid therapy, Athletic Performance

Clinical Trials

Effects of Caffeine in Hydration and Energy Metabolism

Not Applicable

Completed

Conditions: Caffeine

Interventions: Drug: Placebo
Drug: Caffeine

First Posted Date: 2011-11-22

Last Posted Date: 2011-11-22

Lead Sponsor: Technical University of Lisbon

Target Recruit Count: 30

Registration Number: NCT01477294

Locations: 🇵🇹
Faculty of Human Kinetics, Lisbon, Portugal

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Phase 4

Completed

Conditions: Gastrointestinal Stroma Tumor
Non Small-cell Lung Cancer
Renal-cell Cancer

First Posted Date: 2011-07-26

Last Posted Date: 2016-02-02

Lead Sponsor: Markus Joerger

Target Recruit Count: 54

Registration Number: NCT01402089

Locations: 🇨🇭
Cantonal Hospital St.Gallen, St.Gallen, Switzerland

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Phase 1

Completed

Conditions: Infectious Disease

Interventions: Drug: MK-7655
Drug: Imipenem + Cilastatin
Drug: Caffeine
Drug: Midazolam
Drug: Omeprazole

First Posted Date: 2011-01-12

Last Posted Date: 2020-06-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 49

Registration Number: NCT01275170

The Effect of Caffeine in Elderly Citizen Following Eight Hour Abstinence From Caffeine Containing Drinks & Foods

Phase 4

Completed

Conditions: Healthy
Elderly

Interventions: Drug: Caffeine

First Posted Date: 2010-01-13

Last Posted Date: 2010-01-13

Lead Sponsor: Herning Hospital

Target Recruit Count: 30

Registration Number: NCT01048515

Locations: 🇩🇰
Surgical Research Department, Herning, Midtjylland, Denmark

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: Caffeine
Drug: Ketoconazole
Drug: Rosiglitazone
Drug: Fluconazole
Drug: Flurbiprofen
Drug: Rifampin
Drug: Omeprazole
Drug: Dextromethorphan
Drug: Midazolam
Drug: Rosuvastatin

First Posted Date: 2009-08-24

Last Posted Date: 2018-01-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 87

Registration Number: NCT00964106

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Chicago Social Drinking Project

Not Applicable

Recruiting

Conditions: Alcoholism

Interventions: Drug: Placebo
Drug: Diphenhydramine
Drug: Ethanol
Drug: Caffeine

First Posted Date: 2009-08-19

Last Posted Date: 2024-01-29

Lead Sponsor: University of Chicago

Target Recruit Count: 800

Registration Number: NCT00961792

Locations: 🇺🇸
Clinical Addictions Research Laboratory, Chicago, Illinois, United States

AZD2066 Cocktail Study

Phase 1

Completed

Conditions: Chronic Pain

Interventions: Drug: AZD2066
Drug: Caffeine
Drug: Tolbutamide
Drug: Omeprazole Tablet, 20 mg
Drug: Midazolam Tablet, 7.5 mg

First Posted Date: 2009-06-30

Last Posted Date: 2009-10-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT00930306

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Efficacy of Caffeine Injection as an Adjuvant to Opioid Therapy in Cancer Pain

Phase 2

Completed

Conditions: Cancer
Pain

Interventions: Drug: Normal saline
Drug: Caffeine

First Posted Date: 2009-04-10

Last Posted Date: 2011-03-29

Lead Sponsor: Korea Research Foundation

Target Recruit Count: 41

Registration Number: NCT00879775

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷
National Health Insurance Corporation Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of